GLENMARK.NS Balance Sheet
Glenmark Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 22:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹39.04 Bn | ₹31.18 Bn | ₹33.19 Bn | ₹38.90 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹11.15 Bn | ₹4.19 Bn | ₹5.42 Bn | ₹4.28 Bn | CapitalWorkInProgress |
| Goodwill | ₹0.74 Bn | ₹0.67 Bn | ₹0.70 Bn | ₹0.83 Bn | Goodwill |
| Other Intangible Assets | ₹22.25 Bn | ₹10.25 Bn | ₹10.97 Bn | ₹19.42 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.45 Bn | ₹7.90 Bn | ₹0.56 Bn | ₹0.42 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹1.54 Bn | ₹1.49 Bn | ₹1.79 Bn | ₹4.28 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹94.98 Bn | ₹69.31 Bn | ₹67.54 Bn | ₹86.08 Bn | NoncurrentAssets |
| Inventories | ₹29.78 Bn | ₹25.13 Bn | ₹30.29 Bn | ₹34.31 Bn | Inventories |
| Trade Receivables | ₹40.99 Bn | ₹18.58 Bn | ₹33.42 Bn | ₹49.63 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹14.43 Bn | ₹16.58 Bn | ₹16.76 Bn | ₹11.75 Bn | CashAndCashEquivalents |
| Current Investments | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | CurrentInvestments |
| Other Current Assets | ₹11.54 Bn | ₹12.24 Bn | N/A | ₹15.05 Bn | OtherCurrentAssets |
| Total Current Assets | ₹98.74 Bn | ₹74.28 Bn | ₹92.95 Bn | ₹113.00 Bn | CurrentAssets |
| Total Assets | ₹193.72 Bn | ₹143.59 Bn | ₹160.50 Bn | ₹199.08 Bn | Assets |
| Equity Share Capital | ₹0.28 Bn | ₹0.28 Bn | ₹0.28 Bn | ₹0.28 Bn | EquityShareCapital |
| Other Equity | ₹94.46 Bn | ₹78.20 Bn | ₹88.21 Bn | ₹104.84 Bn | OtherEquity |
| Equity Attributable to Owners | ₹94.74 Bn | ₹78.48 Bn | ₹88.49 Bn | ₹105.12 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹3.65 Bn | ₹-0.00 Bn | ₹-0.00 Bn | ₹-0.00 Bn | NonControllingInterest |
| Total Equity | ₹98.39 Bn | ₹78.48 Bn | ₹88.49 Bn | ₹105.12 Bn | Equity |
| Long-term Borrowings | ₹38.52 Bn | ₹0.00 Bn | ₹5.13 Bn | ₹0.00 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹44.87 Bn | ₹6.92 Bn | ₹12.33 Bn | ₹30.20 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹4.96 Bn | ₹9.91 Bn | ₹16.81 Bn | ₹0.00 Bn | BorrowingsCurrent |
| Trade Payables | ₹23.92 Bn | ₹25.36 Bn | ₹25.80 Bn | ₹37.44 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹1.95 Bn | ₹2.44 Bn | ₹1.99 Bn | ₹8.62 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹50.46 Bn | ₹58.19 Bn | ₹59.67 Bn | ₹63.76 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹193.72 Bn | ₹143.59 Bn | ₹160.50 Bn | ₹199.08 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLENMARK.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).